Decoy Therapeutics Inc.
DCOY · XNASCIK 1615219fmd_1867FXMP2DYEWAQP13W8PKKCHSManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Sep 30, 2026, 50 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 1 | 2 | 3 | 5 | 2 | 0 | – | – | – |
| Cost of revenue | 1 | 1 | 0 | – | – | – | – | – | – | – |
| Gross profit | 0 | 1 | 2 | – | – | – | – | – | – | – |
| Research and development | 20 | 17 | 1 | 4 | 7 | 9 | 16 | 7 | 1 | 0 |
| Total operating expenses | 41 | 36 | 4 | 12 | 13 | 15 | 32 | 13 | 6 | 13 |
| Operating income | (40) | (35) | (2) | (8) | (8) | (13) | (32) | (13) | (6) | (13) |
| Income before taxes | – | – | – | – | – | – | – | – | – | – |
| Income tax expense | – | – | – | 0 | – | – | – | – | – | 0 |
| Net income from continuing operations | – | – | (2) | (7) | (7) | – | – | – | – | – |
| Net income | (39) | (34) | (2) | (7) | (7) | (13) | (32) | (13) | (6) | (13) |
| Net income to common shareholders | (39) | (34) | (22) | (7) | (8) | (13) | (32) | (13) | (6) | – |